Methods for treating immune disorders associated with graft transplantation with soluble CTLA4 mutant molecules
US7482327B2 · kind B2 · utility
17Cited by
11References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2006 |
| Grant date | Jan 27, 2009 |
| Priority date | — |
| Expiry date | Apr 6, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.